APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hospital-Acquired Pneumonia (HAP) Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Hospital-Acquired Pneumonia (HAP) Drugs Industry Research Report 2026

22 December 2025122 pages

Choose your research edition.

Industry ResearchHospital-Acquired Pneumonia (HAP) Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Hospital-Acquired Pneumonia (HAP) Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hospital-Acquired Pneumonia (HAP) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Hospital-Acquired Pneumonia (HAP) Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs include Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Novartis, Merck, Mylan, Pfizer, AstraZeneca, Theravance Biopharma and The Medicines Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Hospital-Acquired Pneumonia (HAP) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Hospital-Acquired Pneumonia (HAP) Drugs Market by Company

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Novartis

Merck

Mylan

Pfizer

AstraZeneca

Theravance Biopharma

The Medicines Company

Shinogi

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Type

Antiviral

Antibacterial

Antifungal

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Application

Hospitals

Clinics

Others

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital-Acquired Pneumonia (HAP) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hospital-Acquired Pneumonia (HAP) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital-Acquired Pneumonia (HAP) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Hospital-Acquired Pneumonia (HAP) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Hospital-Acquired Pneumonia (HAP) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Hospital-Acquired Pneumonia (HAP) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units) of Manufacturers (2021-2026) Table 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Hospital-Acquired Pneumonia (HAP) Drugs Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Product Type & Application Table 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Hospital-Acquired Pneumonia (HAP) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceutical Industries Company Information Table 19. Teva Pharmaceutical Industries Business Overview Table 20. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 22. Teva Pharmaceutical Industries Recent Developments Table 23. Sun Pharmaceutical Industries Company Information Table 24. Sun Pharmaceutical Industries Business Overview Table 25. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 27. Sun Pharmaceutical Industries Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. Merck Company Information Table 34. Merck Business Overview Table 35. Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 37. Merck Recent Developments Table 38. Mylan Company Information Table 39. Mylan Business Overview Table 40. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 42. Mylan Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 47. Pfizer Recent Developments Table 48. AstraZeneca Company Information Table 49. AstraZeneca Business Overview Table 50. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 52. AstraZeneca Recent Developments Table 53. Theravance Biopharma Company Information Table 54. Theravance Biopharma Business Overview Table 55. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 57. Theravance Biopharma Recent Developments Table 58. The Medicines Company Company Information Table 59. The Medicines Company Business Overview Table 60. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 62. The Medicines Company Recent Developments Table 63. Shinogi Company Information Table 64. Shinogi Business Overview Table 65. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 67. Shinogi Recent Developments Table 68. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2026) & (k units) Table 70. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2021-2026) Table 71. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2027-2032) & (k units) Table 72. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2027-2032) Table 73. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2021-2026) Table 75. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2027-2032) Table 77. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 79. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 80. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 84. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 85. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 89. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 90. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 94. South America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 95. South America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 99. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 100. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 103. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2027-2032) & (k units) Table 104. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2021-2026) Table 105. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2027-2032) Table 106. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2021-2026) Table 109. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2027-2032) Table 110. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Type (2021-2026) & (US$/unit) Table 111. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Type (2027-2032) & (US$/unit) Table 112. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 113. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2027-2032) & (k units) Table 114. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2021-2026) Table 115. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2027-2032) Table 116. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2021-2026) Table 119. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2027-2032) Table 120. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2021-2026) & (US$/unit) Table 121. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2027-2032) & (US$/unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Hospital-Acquired Pneumonia (HAP) Drugs Distributors List Table 125. Hospital-Acquired Pneumonia (HAP) Drugs Customers List Table 126. Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends Table 127. Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers Table 128. Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Hospital-Acquired Pneumonia (HAP) Drugs Product Image Figure 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (2021-2032) & (k units) Figure 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Average Price (US$/unit) & (2021-2032) Figure 9. Antiviral Product Image Figure 10. Antibacterial Product Image Figure 11. Antifungal Product Image Figure 12. Hospitals Product Image Figure 13. Clinics Product Image Figure 14. Others Product Image Figure 15. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Hospital-Acquired Pneumonia (HAP) Drugs Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region in 2025 Figure 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region in 2025 Figure 22. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country in 2025 Figure 23. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 24. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2021-2032) Figure 25. United States Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country in 2025 Figure 29. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 30. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2021-2032) Figure 31. Germany Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country in 2025 Figure 42. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2021-2032) Figure 44. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country in 2025 Figure 53. South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 54. South America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2021-2032) Figure 55. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country in 2025 Figure 59. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2021-2032) Figure 61. Egypt Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2021-2032) Figure 67. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2021-2032) Figure 68. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (US$/unit) by Type (2021-2032) Figure 69. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2021-2032) Figure 70. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2021-2032) Figure 71. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (US$/unit) by Application (2021-2032) Figure 72. Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Figure 73. Hospital-Acquired Pneumonia (HAP) Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Antiviral
  • Antibacterial
  • Antifungal
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Novartis
  • Merck
  • Mylan
  • Pfizer
  • AstraZeneca
  • Theravance Biopharma
  • The Medicines Company
  • Shinogi

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size (2021-2032)
  4. 2.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (2021-2032)
  5. 2.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Average Price (2021-2032)
  6. 2.3 Hospital-Acquired Pneumonia (HAP) Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Antiviral
  9. 2.3.3 Antibacterial
  10. 2.3.4 Antifungal
  11. 2.4 Hospital-Acquired Pneumonia (HAP) Drugs by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospitals
  14. 2.4.3 Clinics
  15. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Hospital-Acquired Pneumonia (HAP) Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Established Date
  9. 3.9 Global Hospital-Acquired Pneumonia (HAP) Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical Industries
  2. 4.1.1 Teva Pharmaceutical Industries Company Information
  3. 4.1.2 Teva Pharmaceutical Industries Business Overview
  4. 4.1.3 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 4.2 Sun Pharmaceutical Industries
  8. 4.2.1 Sun Pharmaceutical Industries Company Information
  9. 4.2.2 Sun Pharmaceutical Industries Business Overview
  10. 4.2.3 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  12. 4.2.5 Sun Pharmaceutical Industries Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Merck
  20. 4.4.1 Merck Company Information
  21. 4.4.2 Merck Business Overview
  22. 4.4.3 Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  24. 4.4.5 Merck Recent Developments
  25. 4.5 Mylan
  26. 4.5.1 Mylan Company Information
  27. 4.5.2 Mylan Business Overview
  28. 4.5.3 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  30. 4.5.5 Mylan Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 AstraZeneca
  38. 4.7.1 AstraZeneca Company Information
  39. 4.7.2 AstraZeneca Business Overview
  40. 4.7.3 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  42. 4.7.5 AstraZeneca Recent Developments
  43. 4.8 Theravance Biopharma
  44. 4.8.1 Theravance Biopharma Company Information
  45. 4.8.2 Theravance Biopharma Business Overview
  46. 4.8.3 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  48. 4.8.5 Theravance Biopharma Recent Developments
  49. 4.9 The Medicines Company
  50. 4.9.1 The Medicines Company Company Information
  51. 4.9.2 The Medicines Company Business Overview
  52. 4.9.3 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  54. 4.9.5 The Medicines Company Recent Developments
  55. 4.10 Shinogi
  56. 4.10.1 Shinogi Company Information
  57. 4.10.2 Shinogi Business Overview
  58. 4.10.3 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  60. 4.10.5 Shinogi Recent Developments
5 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Scenario by Region
  1. 5.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2027-2032
  5. 5.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Analysis
  2. 8.1.1 Hospital-Acquired Pneumonia (HAP) Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Hospital-Acquired Pneumonia (HAP) Drugs Production Mode & Process
  5. 8.2 Hospital-Acquired Pneumonia (HAP) Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Hospital-Acquired Pneumonia (HAP) Drugs Distributors
  8. 8.2.3 Hospital-Acquired Pneumonia (HAP) Drugs Customers
9 Global Hospital-Acquired Pneumonia (HAP) Drugs Analyzing Market Dynamics
  1. 9.1 Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends
  2. 9.2 Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers
  3. 9.3 Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges
  4. 9.4 Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst